Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883283 | 0.92 | CTSC (0.47) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL20204691 | 0.91 | CTSC (0.58) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL20204693 | 0.91 | CTSC (0.58) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL5670189 | 0.87 | CTSC (0.55) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL23463561 | 0.85 | CTSB (0.58) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL19166213 | 0.85 | CTSB (0.54) | CTSCSLC7A5CTSBCAPN1BACE1 | |
| SCHEMBL14391828 | 0.85 | CTSB (0.54) | CTSCSLC7A5CTSBCAPN1BACE1 | |
| SCHEMBL4318867 | 0.82 | CTSC (0.50) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL17740064 | 0.82 | MMP2 (0.55) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL9572282 | 0.82 | CTSK (0.65) | CTSCCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20140220056-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| WO-2013142961-A1 | EGFL7 TARGETING AND/OR BINDING POLYPEPTIDES AND METHODS FOR INHIBITING ANGIOGENESIS | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2013-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140220056-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | CD4, IFNG, CD69 | CTSC 2590/4885ALPI 812/4885PKM 3991/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | CTSC 297/4885ALPI 3892/4885PKM 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.